Research at UNT Health Science Center suggests that depression and diabetes may be of particular importance in this population and even that the blood profile of Alzheimer’s is different among Mexican Americans as compared to non-Hispanic whites.
A new drug may improve memory problems in people with moderate Alzheimer’s disease, according to a phase IIa study released today that will be presented at the American Academy of Neurology’s 65th Annual Meeting in San Diego, March 16 to 23, 2013. The drug is called ORM-12741.
Sleep is disrupted in people who likely have early Alzheimer’s disease but do not yet have the memory loss or other problems characteristic of full-blown disease, researchers report March 11 in JAMA Neurology.
An anti-atherosclerosis drug greatly reduced blood-brain barrier (BBB) leaks in animal models with diabetes and hypercholesterolemia and linked BBB permeability with amyloid peptide deposits at the site of early Alzheimer's pathology.
Studies in mice with Alzheimer’s disease (AD) have shown that sodium phenylbutyrate, known as Buphenyl, successfully increases factors for neuronal growth and protects learning and memory, according to neurological researchers at the Rush University Medical Center.
At the Keystone Symposium “New Frontiers in Neurodegenerative Disease Research,” held 4-7 February in Santa Fe, New Mexico, researchers explored the processes that lead to a variety of diseases, including Alzheimer’s and Lou Gehrig’s disease (amyotrophic lateral sclerosis, ALS). Several presenters described damage that genes undergo as people age, pointing to DNA breaks as a potential step on the way to disease. Others discussed a new component of the protein tangles that characterize Alzheimer's disease. Researchers also reported progress in understanding how two proteins, TDP-43 and FUS, cause ALS. See Alzforum’s four-part series
UCLA scientists have discovered a new genetic risk factor for Alzheimer's disease by screening people's DNA and then using an advanced type of scan to visualize their brains' connections.
Researchers at the University of Michigan have found a new potential benefit of a molecule in green tea: preventing the misfolding of specific proteins in the brain.
Researchers have identified a possible treatment window of several years for plaques in the brain that are thought to cause memory loss in diseases such as Alzheimer’s. The Mayo Clinic study is published in the Feb. 27 online issue of Neurology, the medical journal of the American Academy of Neurology.
A novel way to image the brain’s glymphatic pathway may provide the basis for a new strategy to evaluate Alzheimer's disease susceptibility, according to a research paper published in The Journal of Clinical Investigation.
New findings by Columbia researchers suggest that along with amyloid deposits, white matter hyperintensities (WMHs) may be a second necessary factor for the development of Alzheimer’s disease.
Scientists are getting serious about tackling Alzheimer's disease with multiple drugs. Going after one target at a time has not proven successful, and some researchers believe that new drugs may not work well alone. Instead, they want to develop combination therapies. It worked for AIDS and cancer—why not Alzheimer’s?
At the 7th Human Amyloid Imaging conference held in Miami, Florida, 250 experts discussed the hottest topics in Alzheimer’s brain imaging. What’s in store for 2013? Read about new compounds that image tau—one of the disease’s toxic proteins, ground rules for scanning patients for plaques, and a plan to unify scan measures.
The number of people with Alzheimer’s disease is expected to triple in the next 40 years, according to a new study published in the February 6, 2013, online issue of Neurology®, the medical journal of the American Academy of Neurology.
The number of people with Alzheimer’s disease is expected to triple in the next 40 years, according to a new study by researchers from Rush University Medical Center published in the February 6, 2013, online issue of Neurology, the medical journal of the American Academy of Neurology.
A team of academic researchers has pinpointed how vitamin D3 and omega-3 fatty acids may enhance the immune system's ability to clear the brain of amyloid plaques, one of the hallmarks of Alzheimer's disease. In a small pilot study, the scientists identified key genes and signaling networks regulated by vitamin D3 and the omega-3 fatty acid DHA (docosahexaenoic acid) that may help control inflammation and improve plaque clearance.
A group of recipients of cadaver-derived human growth hormone (c-hGH) does not appear to be at increased risk for Alzheimer and Parkinson disease despite their likely exposure to neurodegenerative disease (ND)-associated proteins and elevated risk of infectious prion protein-related disease, according to a report published Online First by JAMA Neurology, a JAMA Network publication.
A research team in Israel has devised a novel approach to identifying the molecular basis for designing a drug that might one day decrease the risk diabetes patients face of developing Alzheimer's disease. The team will present its work at the 57th Annual Meeting of the Biophysical Society (BPS), held Feb. 2-6, 2013, in Philadelphia, Pa.
New evidence shows the root of heart failure lies in misfolded proteins in the heart’s cells, according to University of North Carolina School of Medicine researchers. The finding may pave the way for dramatically new treatment approaches.
In experiments on rats outfitted with tiny goggles, scientists say they have learned that the brain’s initial vision processing center not only relays visual stimuli, but also can “learn” time intervals and create specifically timed expectations of future rewards. The research sheds new light on learning and memory-making, the investigators say, and could help explain why people with Alzheimer’s disease have trouble remembering recent events.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right